BACKGROUND. In systemic amyloidosis the distribution and progression of disease have been difficult to monitor, because they can be demonstrated only by biopsy. Serum amyloid P component (SAP) is a normal circulating plasma protein that is deposited on amyloid fibrils because of its specific binding affinity for them. We investigated whether labeled SAP could be used to locate amyloid deposits. METHODS. Purified human SAP labeled with iodine-123 was given intravenously to 50 patients with biopsy-proved systemic amyloidosis--25 with the AL (primary) type and 25 with the AA (secondary) type--and to 26 control patients with disease and 10 healthy subjects. Whole-body images and regional views were obtained after 24 hours and read in a blinded fashion. RESULTS. In the patients with amyloidosis the 123I-SAP was localized rapidly and specifically in amyloid deposits. The scintigraphic images obtained were characteristic and appeared to identify the extent of amyloid deposition in all 50 patients. There was no uptake of the 123I-SAP by the control patients and the healthy subjects. In all patients with AA amyloidosis the spleen was affected, whereas the scans showed uptake in the heart, skin, carpal region, and bone marrow only in patients with the AL type. Positive images were seen in six patients in whom biopsies had been negative or unsuccessful; in all six, amyloid was subsequently found on biopsy or at autopsy. Progressive amyloid deposition was observed in 9 of 11 patients studied serially. CONCLUSIONS. Scintigraphy after the injection of 123I-SAP can be used for diagnosing, locating, and monitoring the extent of systemic amyloidosis.
Source Information
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
This article has been cited by other articles:
van Gameren, I. I., van Rijswijk, M. H., Bijzet, J., Vellenga, E., Hazenberg, B. P.
(2009). Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. haematol
94: 1094-1100
[Abstract][Full Text]
Gillmore, J. D., Lachmann, H. J., Rowczenio, D., Gilbertson, J. A., Zeng, C.-H., Liu, Z.-H., Li, L.-S., Wechalekar, A., Hawkins, P. N.
(2009). Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen A{alpha}-Chain Amyloidosis. J. Am. Soc. Nephrol.
20: 444-451
[Abstract][Full Text]
Wechalekar, A. D., Lachmann, H. J., Goodman, H. J. B., Bradwell, A., Hawkins, P. N., Gillmore, J. D.
(2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood
112: 4009-4016
[Abstract][Full Text]
Wechalekar, A. D., Lachmann, H. J., Offer, M., Hawkins, P. N., Gillmore, J. D.
(2008). Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. haematol
93: 295-298
[Abstract][Full Text]
Lachmann, H. J., Goodman, H. J.B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., Hawkins, P. N.
(2007). Natural History and Outcome in Systemic AA Amyloidosis. NEJM
356: 2361-2371
[Abstract][Full Text]
Hazenberg, B. P.C., van Rijswijk, M. H., Lub-de Hooge, M. N., Vellenga, E., Haagsma, E. B., Posthumus, M. D., Jager, P. L.
(2007). Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis. JNM
48: 865-872
[Abstract][Full Text]
Wechalekar, A. D., Goodman, H. J. B., Lachmann, H. J., Offer, M., Hawkins, P. N., Gillmore, J. D.
(2007). Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood
109: 457-464
[Abstract][Full Text]
Wall, J. S., Kennel, S. J., Paulus, M., Gregor, J., Richey, T., Avenell, J., Yap, J., Townsend, D., Weiss, D. T., Solomon, A.
(2006). Radioimaging of Light Chain Amyloid with a Fibril-Reactive Monoclonal Antibody. JNM
47: 2016-2024
[Abstract][Full Text]
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., Hawkins, P. N.
(2006). Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations. Arch Dermatol
142: 1591-1597
[Abstract][Full Text]
Lachmann, H J, Hawkins, P N
(2006). Amyloidosis and the lung. Chronic Respiratory Disease
3: 203-214
[Abstract]
Connolly, J.O., Gillmore, J.D., Lachmann, H.J., Davenport, A., Hawkins, P.N., Woolfson, R.G.
(2006). Renal amyloidosis in intravenous drug users. QJM
99: 737-742
[Abstract][Full Text]
Sanchorawala, V.
(2006). Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. CJASN
1: 1331-1341
[Abstract][Full Text]
O'Nuallain, B., Hrncic, R., Wall, J. S., Weiss, D. T., Solomon, A.
(2006). Diagnostic and Therapeutic Potential of Amyloid-Reactive IgG Antibodies Contained in Human Sera.. J. Immunol.
176: 7071-7078
[Abstract][Full Text]
Gillmore, J. D., Goodman, H. J., Lachmann, H. J., Offer, M., Wechalekar, A. D., Joshi, J., Pepys, M. B., Hawkins, P. N.
(2006). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood
107: 1227-1229
[Abstract][Full Text]
Perugini, E., Guidalotti, P. L., Salvi, F., Cooke, R. M.T., Pettinato, C., Riva, L., Leone, O., Farsad, M., Ciliberti, P., Bacchi-Reggiani, L., Fallani, F., Branzi, A., Rapezzi, C.
(2005). Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. J Am Coll Cardiol
46: 1076-1084
[Abstract][Full Text]
Maceira, A. M., Joshi, J., Prasad, S. K., Moon, J. C., Perugini, E., Harding, I., Sheppard, M. N., Poole-Wilson, P. A., Hawkins, P. N., Pennell, D. J.
(2005). Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation
111: 186-193
[Abstract][Full Text]
Moon, A. O., Calamia, K. T., Walsh, J. S.
(2003). Nodular Amyloidosis: Review and Long-term Follow-up of 16 Cases. Arch Dermatol
139: 1157-1159
[Abstract][Full Text]
Schaadt, B. K., Hendel, H. W., Gimsing, P., Jonsson, V., Pedersen, H., Hesse, B.
(2003). 99mTc-Aprotinin Scintigraphy in Amyloidosis. JNM
44: 177-183
[Abstract][Full Text]
Mpofu, S., Teh, L. S., Smith, P. J., Moots, R. J., Hawkins, P. N.
(2003). Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford)
42: 362-366
[Abstract][Full Text]
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., Hawkins, P. N.
(2002). Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. NEJM
346: 1786-1791
[Abstract][Full Text]
Saraiva, M. J. M.
(2002). Sporadic Cases of Hereditary Systemic Amyloidosis. NEJM
346: 1818-1819
[Full Text]
Lachmann, H.J., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N., Pepys, M.B.
(2002). Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM
95: 211-218
[Abstract][Full Text]
Dember, L. M., Sanchorawala, V., Seldin, D. C., Wright, D. G., LaValley, M., Berk, J. L., Falk, R. H., Skinner, M.
(2001). Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosis-Associated Renal Disease. ANN INTERN MED
134: 746-753
[Abstract][Full Text]
Dubrey, S W, Burke, M M, Khaghani, A, Hawkins, P N, Yacoub, M H, Banner, N R
(2001). Long term results of heart transplantation in patients with amyloid heart disease. Heart
85: 202-207
[Abstract][Full Text]
Drewe, E., McDermott, E. M., Powell, R. J.
(2000). Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor-Associated Periodic Syndrome. NEJM
343: 1044-1045
[Full Text]
Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Rahman, V., Stangou, A.J., Pepys, M.B., Hawkins, P.N.
(2000). Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen {alpha}-chain variant in an English family. QJM
93: 269-275
[Abstract][Full Text]
Booth, D.R., Gillmore, J.D., Lachmann, H.J., Booth, S.E., Bybee, A., Soyturk, M., Akar, S., Pepys, M.B., Tunca, M., Hawkins, P.N.
(2000). The genetic basis of autosomal dominant familial Mediterranean fever. QJM
93: 217-221
[Abstract][Full Text]
Gillmore, J. D, Hawkins, P. N
(1999). Amyloidosis and the respiratory tract. Thorax
54: 444-451
[Full Text]
Brett, M., Persey, M. R., Reilly, M. M., Revesz, T., Booth, D. R., Booth, S. E., Hawkins, P. N., Pepys, M. B., Morgan-Hughes, J. A.
(1999). Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain
122: 183-190
[Abstract][Full Text]
Lovat, L B, Persey, M R, Madhoo, S, Pepys, M B, Hawkins, P N
(1998). The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut
42: 727-734
[Abstract][Full Text]
HAWKINS, P. N
(1997). Diagnosis and treatment of amyloidosis. Ann Rheum Dis
56: 631-633
[Full Text]
Falk, R. H., Comenzo, R. L., Skinner, M.
(1997). The Systemic Amyloidoses. NEJM
337: 898-909
[Full Text]
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., Therneau, T. M.
(1997). A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. NEJM
336: 1202-1207
[Abstract][Full Text]
Kerner, M. M., Wang, M. B., Angier, G., Calcaterra, T. C., Ward, P. H.
(1995). Amyloidosis of the Head and Neck: A Clinicopathologic Study of the UCLA Experience, 1955-1991. Arch Otolaryngol Head Neck Surg
121: 778-782
[Abstract]
Booth, D. R., Tan, S. Y., Hawkins, P. N., Pepys, M. B., Frustaci, A.
(1995). A Novel Variant of Transthyretin, 59Thr->Lys, Associated With Autosomal Dominant Cardiac Amyloidosis in an Italian Family. Circulation
91: 962-967
[Abstract][Full Text]
Hall, R, Hawkins, P N
(1994). Grand Rounds - Hammersmith Hospital: Cardiac transplantation for AL amyloidosis. BMJ
309: 1135-1137
[Full Text]
Previous
